The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Long-acting (LA) glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) that require injection once a week or less are now available to prescribers in the form of Bydureon®(once-weekly exenatide).

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists ... alongside other drugs such as AstraZeneca's Bydureon (exenatide), GlaxoSmithKline's Tanzeum ...